Dexcom’s CEO Joins Let’s Talk Medtech for a Candid Discussion on Firm’s FutureDexcom’s CEO Joins Let’s Talk Medtech for a Candid Discussion on Firm’s Future

No topic is off-limits, as Dexcom CEO Kevin Sayer gives an update on the G7 CGM; discusses the competitive landscape; and talks about the collaboration with Nick Jonas.

Omar Ford

June 29, 2021

1 Min Read
Let's Talk Medtech guest Dexcom CEO
Image courtesy of Dexcom

 

IMG_Jun292021at22713PM.png

The role of Continuous Glucose Monitoring is growing in diabetes management – and Dexcom aims to be the frontrunner in the space. The San Diego, CA-based company has its G7 CGM on the horizon; solid studies that were presented at the American Diabetes Association 81st Scientific Sessions; diabetes driving telemedicine; and even that Super Bowl Commercial collaboration with Nick Jonas.

Dexcom’s CEO Kevin Sayer checks in for this episode of Let’s Talk Medtech and discusses the company’s recent activities and paints a picture of what the future of CGM will look like.

 

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like